IPHARMA obtained an approval to conduct the clinical trial of a drug against COVID-19

IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct a Phase II clinical trial of the drug CKD-314.


The investigational drug developer is the Chong Kun Dang Pharmaceutical Corporation (Republic of Korea).


Protocol № A108_02CVD2014 "Ab open-label multicenter randomized double-blind controlled study to evaluate the efficacy and safety of CKD-314 in hospitalized adult patients diagnosed with COVID-19 pneumonia".


The purpose is to evaluate the efficacy and safety of CKD-314 in hospitalized adult patients diagnosed with COVID-19 pneumonia.


The study will be conducted in 24 clinical sites.

Недавние посты
Архив

© 2021 IPHARMA

  • Facebook Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon